Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 04, 2025 08:30 ET | Source: SAB Biotherapeutics, Inc.

SAB BIO to Present Data at the International Society for Pediatric and Adolescent Diabetes Annual Conference Showcasing Progress in the Development of SAB-142

MIAMI, Nov. 04, 2025 (GLOBE NEWSWIRE) -- SAb Biotherapeutics, Inc. (Nasdaq: SABS), a clinical-stage biopharmaceutical company developing human anti-thymocyte immunoglobulin (hATG) for type 1...
November 04, 2025 08:00 ET | Source: SAB Biotherapeutics, Inc.

SAB BIO to Participate in Upcoming Investor Conferences

MIAMI, Nov. 04, 2025 (GLOBE NEWSWIRE) -- SAb Biotherapeutics, Inc. (Nasdaq: SABS), a clinical-stage biopharmaceutical company developing human anti-thymocyte immunoglobulin (hATG) for autoimmune...
September 19, 2025 07:24 ET | Source: SAB Biotherapeutics, Inc.

SAB BIO Highlights Data in Multiple Presentations at EASD

-As SAB initiates its Phase 2b SAFEGUARD study for SAB-142 in new-onset Stage 3 autoimmune T1D patients, EASD provided an opportunity to connect with many T1D thought leaders that will participate in...
September 03, 2025 16:05 ET | Source: SAB Biotherapeutics, Inc.

SAB BIO to Deliver Five Presentations Related to SAB-142 at the 2025 Annual Meeting of the European Association for the Study of Diabetes

MIAMI, Sept. 03, 2025 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), (“SAB BIO” or the “Company”), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that...
August 07, 2025 07:30 ET | Source: SAB Biotherapeutics, Inc.

SAB BIO Reports Second Quarter Financial Results and Highlights Company Updates

SAB BIO Reports Second Quarter Financial Results and Highlights Company Updates
July 21, 2025 07:30 ET | Source: SAB Biotherapeutics, Inc.

SAB BIO Announces Oversubscribed $175 Million Private Placement

SAB BIO Announces Oversubscribed $175 Million Private Placement
May 09, 2025 09:00 ET | Source: SAB Biotherapeutics, Inc.

SAB BIO Announces Q1 2025 Financial Results and Provides Company Updates

MIAMI, May 09, 2025 (GLOBE NEWSWIRE) -- SAB BIO (Nasdaq: SABS), (“SAB BIO” or the “Company”), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that is developing human...
March 31, 2025 07:32 ET | Source: SAB Biotherapeutics, Inc.

SAB BIO Reports Full Year 2024 Operating and Financial Results

MIAMI, March 31, 2025 (GLOBE NEWSWIRE) -- SAB BIO (Nasdaq: SABS), (“SAB BIO” or the “Company”), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that is developing...
January 31, 2025 07:00 ET | Source: SAB Biotherapeutics, Inc.

SAB BIO to Participate in Upcoming Investor Conferences

MIAMI, Jan. 31, 2025 (GLOBE NEWSWIRE) -- SAB BIO (Nasdaq: SABS), (“SAB BIO” or the “Company”), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that is developing...
January 28, 2025 07:00 ET | Source: SAB Biotherapeutics, Inc.

SAB BIO Announces Positive Topline Phase 1 Clinical Results with Potentially Disease-Modifying T1D Therapy SAB-142

SAB BIO Announces Positive Topline Phase 1 Clinical Results with Potentially Disease-Modifying T1D Therapy SAB-142